Security Snapshot

RAPT Therapeutics, Inc. - Common Stock $0.0001 par value per share (RAPT) Institutional Ownership

CUSIP: 75382E109

13F Institutional Holders and Ownership History from Q4 2019 to Q4 2025

Latest Period

Q4 2025

Institutions Reporting

3

Shares (Excl. Options)

2,962,707

Price

$33.87

Save this security page for your next review

Keep this CUSIP in your watchlists so you can revisit quarter changes from one place.

Create free account to save this page Review latest holder period
Type / Class
Equity / Common Stock $0.0001 par value per share
Symbol
RAPT on Nasdaq
Shares outstanding
27,725,634
Price per share
$33.87
All holders as of 31 Dec 2025
Q4 2025
Total 13F shares
2,962,707
Total reported value
$100,346,899
% of total 13F portfolios
0%
Share change
-9,805
Value change
-$332,096
Number of holders
3
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Quick Takeaways

  • RAPT - RAPT Therapeutics, Inc. - Common Stock $0.0001 par value per share is tracked under CUSIP 75382E109.
  • 3 institutions reported positions in Q4 2025.
  • 13 significant owners is listed from Schedule 13D/13G reporting.

What Changed

  • Holder count moved from 3 to 3 between Q3 2025 and Q4 2025.
  • Reported value moved from $76,661,084 to $100,346,899.

Why This Matters

  • You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
  • 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.

Source Evidence

Source: SEC Form 13F

Latest holder context comes from 3 institutions filings for Q4 2025.

Open SEC Evidence

Investment Quick Answers

What is CUSIP 75382E109?
CUSIP 75382E109 identifies RAPT - RAPT Therapeutics, Inc. - Common Stock $0.0001 par value per share in SEC 13F datasets.

Where can I see the latest institutional holders?
Review the Q4 2025 holders report and the ownership history table below.

Significant Owners of RAPT Therapeutics, Inc. - Common Stock $0.0001 par value per share (RAPT) based on Schedule 13D/G filings

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
Medicxi IV LP 17% $19,446,240 22,352,000 Medicxi IV GP Limited 27 Dec 2024
Deep Track Capital, LP 9.9% $12,280,920 14,116,000 Deep Track Capital, LP 23 Dec 2024
Redmile Group, LLC 9.9% $12,121,231 13,932,449 Redmile Group, LLC 31 Dec 2024
TCG Crossover GP II, LLC 10% $11,478,006 13,193,110 TCG Crossover GP II, LLC 27 Dec 2024
Foresite Capital Fund VI LP 9.3% $10,875,000 12,500,000 Foresite Capital Fund VI, L.P. 23 Dec 2024
RTW INVESTMENTS, LP 8.9% $10,234,680 11,764,000 RTW Investments, LP 31 Mar 2025
VANGUARD GROUP INC 6.3% +202% $7,202,554 +$4,651,367 8,278,798 +182% The Vanguard Group 31 Mar 2025
PERCEPTIVE ADVISORS LLC 4.5% $5,115,600 5,880,000 Perceptive Advisors LLC 31 Dec 2024
BlackRock, Inc. 1.7% $2,006,761 2,306,622 BlackRock, Inc. 31 Mar 2025
COLUMN GROUP II, LP 4.9% $1,395,126 1,603,593 Peter Svennilson 23 Dec 2024
GLAZER CAPITAL, LLC 5.4% $50,334,004 1,486,094 Glazer Capital, LLC 02 Feb 2026
ORBIMED ADVISORS LLC 6.6% -33% $28,023,878 -$310,734,477 1,086,618 -92% ORBIMED ADVISORS LLC 30 Sep 2025
FMR LLC 0.4% $418,041 480,507 FMR LLC 31 Jan 2025

As of 31 Dec 2025, 3 institutional investors reported holding 2,962,707 shares of RAPT Therapeutics, Inc. - Common Stock $0.0001 par value per share (RAPT). This represents 11% of the company’s total 27,725,634 outstanding shares.

Top 3 Institutional Shareholders

The largest institutional shareholders of RAPT Therapeutics, Inc. - Common Stock $0.0001 par value per share (RAPT) together control 11% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.

Institution Ownership % Shares Held Share Change % Portfolio % Holdings Value
Medicxi Ventures Management (Jersey) Ltd 10% 2,794,000 0% 11% $94,632,780
Column Group LLC 0.56% 156,270 -5.9% 6.4% $5,292,878
AJU IB Investment Co., Ltd. 0.04% 12,437 0% 2.3% $421,241

Institutional Holders of RAPT Therapeutics, Inc. - Common Stock $0.0001 par value per share (RAPT) across Reporting Periods

Period Reported Shares, Excl. Options Value, Excl. Options Value Change Price (Median) Investors
2025 Q4 2,962,707 $100,346,899 -$332,096 $33.87 3
2025 Q3 2,972,512 $76,661,084 +$42,075,407 $25.79 3
2025 Q2 1,341,050 $10,728,400 -$158,903,455 $8.00 2
2025 Q1 131,135,934 $159,984,594 +$4,424,695 $1.22 89
2024 Q4 126,888,838 $199,480,129 +$130,912,564 $1.58 89
2024 Q3 29,799,656 $59,894,847 -$5,399,235 $2.01 92
2024 Q2 31,808,667 $97,015,342 -$20,514,565 $3.05 100
2024 Q1 31,957,297 $286,976,309 -$135,887,644 $8.98 120
2023 Q4 34,982,104 $869,312,485 +$6,735,986 $24.85 108
2023 Q3 34,763,427 $577,769,050 +$11,319,522 $16.62 96
2023 Q2 34,050,266 $636,743,238 +$14,411,769 $18.70 97
2023 Q1 33,297,098 $610,504,496 +$19,762,513 $18.35 104
2022 Q4 32,051,948 $634,583,743 +$67,138,151 $19.80 92
2022 Q3 29,977,976 $705,685,698 -$6,718,488 $24.06 96
2022 Q2 29,739,176 $542,744,027 +$30,137,398 $18.25 83
2022 Q1 28,022,792 $616,047,645 -$11,376,493 $21.99 82
2021 Q4 26,299,986 $965,984,248 +$58,612,650 $36.73 96
2021 Q3 24,839,747 $731,027,543 +$65,328,555 $31.05 104
2021 Q2 26,596,757 $845,609,249 +$179,542,242 $31.79 107
2021 Q1 20,992,943 $466,036,000 +$14,749,147 $22.20 77
2020 Q4 20,445,788 $403,803,000 +$1,193,976 $19.75 80
2020 Q3 16,829,467 $541,869,734 +$65,277,706 $32.20 66
2020 Q2 14,821,430 $430,109,022 +$93,891,523 $29.02 52
2020 Q1 11,682,494 $247,909,000 +$53,863,363 $21.27 37
2019 Q4 2,361,079 $64,437,000 +$64,437,000 $27.61 25